Olema Historical Financial Ratios

OLMA Stock

USD 4.11 0.09 2.14%

Olema Pharmaceuticals is promptly reporting on over 90 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Olema Pharmaceuticals financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

About Olema Financial Ratios Analysis

Olema PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Olema Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Olema financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Olema Pharmaceuticals history.

Olema Pharmaceuticals Financial Ratios Chart

At present, Olema Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.88, whereas Book Value Per Share is forecasted to decline to 3.73.

Payables Turnover Cash Per Share Days Payables Outstanding Income Quality

Add Fundamental

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Income Quality

An assessment of the sustainability of a company's earnings over time, considering factors like revenue source diversification and cost structure.

Most ratios from Olema Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Olema Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Olema Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.At present, Olema Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's PB Ratio is expected to grow to 0.88, whereas Book Value Per Share is forecasted to decline to 3.73.

	2022	2023	2024	2025 (projected)
Current Ratio	12.62	12.33	10.5	9.98
Net Debt To EBITDA	0.2	0.63	0.97	0.92

Current Ratio Net Debt To E B I T D A

Olema Pharmaceuticals fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield	Net Debt To E B I T D A
Ptb Ratio		0.91	-0.61	-0.86	-0.4	1.0	-0.87	-0.33	-0.61	-0.86	0.67	0.34	0.84	0.98	0.7	-0.41	0.98	-0.38	-0.42	-0.93	0.98	0.99	0.5	0.98	-0.61	0.36
Book Value Per Share	0.91		-0.49	-0.76	-0.24	0.91	-0.76	0.0	-0.47	-0.77	0.56	0.41	0.93	0.83	0.85	-0.47	0.83	-0.03	-0.64	-0.87	0.83	0.9	0.2	0.84	-0.49	0.52
Free Cash Flow Yield	-0.61	-0.49		0.81	0.6	-0.61	0.81	0.08	0.57	0.81	-0.67	-0.09	-0.4	-0.63	-0.57	0.13	-0.63	0.32	0.51	0.79	-0.62	-0.67	-0.14	-0.62	1.0	0.19
Operating Cash Flow Per Share	-0.86	-0.76	0.81		0.63	-0.86	1.0	0.09	0.78	1.0	-0.86	-0.24	-0.68	-0.87	-0.79	0.33	-0.87	0.36	0.6	0.97	-0.86	-0.93	-0.22	-0.86	0.81	0.09
Capex To Depreciation	-0.4	-0.24	0.6	0.63		-0.4	0.62	0.06	0.74	0.58	-0.82	0.6	0.05	-0.41	-0.39	-0.52	-0.41	0.15	0.07	0.53	-0.4	-0.44	-0.09	-0.4	0.58	0.27
Pb Ratio	1.0	0.91	-0.61	-0.86	-0.4		-0.87	-0.33	-0.61	-0.86	0.67	0.34	0.84	0.98	0.7	-0.41	0.98	-0.38	-0.42	-0.93	0.98	0.99	0.5	0.98	-0.61	0.36
Free Cash Flow Per Share	-0.87	-0.76	0.81	1.0	0.62	-0.87		0.09	0.78	1.0	-0.86	-0.25	-0.69	-0.87	-0.79	0.34	-0.87	0.36	0.6	0.97	-0.86	-0.93	-0.22	-0.86	0.81	0.09
Roic	-0.33	0.0	0.08	0.09	0.06	-0.33	0.09		0.05	0.08	-0.06	0.0	-0.02	-0.47	0.44	0.0	-0.47	0.87	-0.61	0.1	-0.46	-0.26	-0.98	-0.46	0.08	-0.03
Inventory Turnover	-0.61	-0.47	0.57	0.78	0.74	-0.61	0.78	0.05		0.77	-0.95	0.12	-0.34	-0.62	-0.59	0.0	-0.62	0.25	0.31	0.68	-0.62	-0.67	-0.14	-0.62	0.57	0.2
Net Income Per Share	-0.86	-0.77	0.81	1.0	0.58	-0.86	1.0	0.08	0.77		-0.85	-0.3	-0.71	-0.87	-0.8	0.38	-0.87	0.36	0.63	0.97	-0.86	-0.93	-0.21	-0.86	0.81	0.08
Days Of Inventory On Hand	0.67	0.56	-0.67	-0.86	-0.82	0.67	-0.86	-0.06	-0.95	-0.85		-0.12	0.39	0.68	0.64	0.01	0.68	-0.29	-0.39	-0.77	0.67	0.73	0.15	0.67	-0.66	-0.22
Payables Turnover	0.34	0.41	-0.09	-0.24	0.6	0.34	-0.25	0.0	0.12	-0.3	-0.12		0.71	0.34	0.3	-0.99	0.34	-0.21	-0.53	-0.31	0.34	0.37	0.08	0.34	-0.1	0.12
Cash Per Share	0.84	0.93	-0.4	-0.68	0.05	0.84	-0.69	-0.02	-0.34	-0.71	0.39	0.71		0.78	0.76	-0.76	0.78	-0.13	-0.68	-0.79	0.79	0.84	0.21	0.79	-0.4	0.45
Pocfratio	0.98	0.83	-0.63	-0.87	-0.41	0.98	-0.87	-0.47	-0.62	-0.87	0.68	0.34	0.78		0.59	-0.41	1.0	-0.55	-0.32	-0.91	1.0	0.97	0.62	1.0	-0.63	0.23
Interest Coverage	0.7	0.85	-0.57	-0.79	-0.39	0.7	-0.79	0.44	-0.59	-0.8	0.64	0.3	0.76	0.59		-0.37	0.59	0.25	-0.87	-0.83	0.59	0.76	-0.26	0.59	-0.57	0.23
Capex To Operating Cash Flow	-0.41	-0.47	0.13	0.33	-0.52	-0.41	0.34	0.0	0.0	0.38	0.01	-0.99	-0.76	-0.41	-0.37		-0.41	0.24	0.56	0.39	-0.41	-0.45	-0.1	-0.41	0.14	-0.1
Pfcf Ratio	0.98	0.83	-0.63	-0.87	-0.41	0.98	-0.87	-0.47	-0.62	-0.87	0.68	0.34	0.78	1.0	0.59	-0.41		-0.55	-0.32	-0.91	1.0	0.97	0.62	1.0	-0.63	0.23
Days Payables Outstanding	-0.38	-0.03	0.32	0.36	0.15	-0.38	0.36	0.87	0.25	0.36	-0.29	-0.21	-0.13	-0.55	0.25	0.24	-0.55		-0.31	0.29	-0.54	-0.39	-0.83	-0.54	0.32	0.35
Income Quality	-0.42	-0.64	0.51	0.6	0.07	-0.42	0.6	-0.61	0.31	0.63	-0.39	-0.53	-0.68	-0.32	-0.87	0.56	-0.32	-0.31		0.63	-0.32	-0.51	0.49	-0.32	0.51	-0.03
Roe	-0.93	-0.87	0.79	0.97	0.53	-0.93	0.97	0.1	0.68	0.97	-0.77	-0.31	-0.79	-0.91	-0.83	0.39	-0.91	0.29	0.63		-0.91	-0.97	-0.25	-0.91	0.79	-0.12
Ev To Operating Cash Flow	0.98	0.83	-0.62	-0.86	-0.4	0.98	-0.86	-0.46	-0.62	-0.86	0.67	0.34	0.79	1.0	0.59	-0.41	1.0	-0.54	-0.32	-0.91		0.98	0.62	1.0	-0.62	0.25
Pe Ratio	0.99	0.9	-0.67	-0.93	-0.44	0.99	-0.93	-0.26	-0.67	-0.93	0.73	0.37	0.84	0.97	0.76	-0.45	0.97	-0.39	-0.51	-0.97	0.98		0.43	0.98	-0.68	0.23
Return On Tangible Assets	0.5	0.2	-0.14	-0.22	-0.09	0.5	-0.22	-0.98	-0.14	-0.21	0.15	0.08	0.21	0.62	-0.26	-0.1	0.62	-0.83	0.49	-0.25	0.62	0.43		0.62	-0.14	0.17
Ev To Free Cash Flow	0.98	0.84	-0.62	-0.86	-0.4	0.98	-0.86	-0.46	-0.62	-0.86	0.67	0.34	0.79	1.0	0.59	-0.41	1.0	-0.54	-0.32	-0.91	1.0	0.98	0.62		-0.62	0.25
Earnings Yield	-0.61	-0.49	1.0	0.81	0.58	-0.61	0.81	0.08	0.57	0.81	-0.66	-0.1	-0.4	-0.63	-0.57	0.14	-0.63	0.32	0.51	0.79	-0.62	-0.68	-0.14	-0.62		0.19
Net Debt To E B I T D A	0.36	0.52	0.19	0.09	0.27	0.36	0.09	-0.03	0.2	0.08	-0.22	0.12	0.45	0.23	0.23	-0.1	0.23	0.35	-0.03	-0.12	0.25	0.23	0.17	0.25	0.19

Click cells to compare fundamentals

Olema Pharmaceuticals Account Relationship Matchups

Olema Pharmaceuticals fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	5.59	1.3	0.5	2.5	0.84	0.88
Book Value Per Share	8.6	7.2	4.94	5.61	6.96	3.73
Free Cash Flow Yield	(0.0105)	(0.14)	(0.84)	(0.13)	(0.3)	(0.32)
Operating Cash Flow Per Share	(0.51)	(1.28)	(2.05)	(1.85)	(1.78)	(1.87)
Pb Ratio	5.59	1.3	0.5	2.5	0.84	0.88
Free Cash Flow Per Share	(0.51)	(1.32)	(2.06)	(1.85)	(1.78)	(1.87)
Roic	(0.0655)	(0.25)	(0.52)	(0.41)	(0.35)	(0.33)
Net Income Per Share	(0.58)	(1.79)	(2.56)	(2.14)	(2.2)	(2.31)
Payables Turnover	0.0153	72.3	4.43	0.14	0.13	0.12
Cash Per Share	8.61	14.19	5.11	5.79	7.39	4.72
Pocfratio	(95.13)	(7.3)	(1.19)	(7.58)	(3.28)	(3.45)
Pfcf Ratio	(94.87)	(7.08)	(1.19)	(7.58)	(3.28)	(3.45)
Days Payables Outstanding	23.9K	5.05	82.33	2.6K	3.0K	2.9K
Roe	(0.0673)	(0.25)	(0.52)	(0.38)	(0.32)	(0.3)
Ev To Operating Cash Flow	(78.09)	(1.7)	(0.94)	(6.79)	(1.96)	(2.06)
Pe Ratio	(83.03)	(5.22)	(0.96)	(6.57)	(2.65)	(2.78)
Return On Tangible Assets	(0.0664)	(0.24)	(0.48)	(0.35)	(0.29)	(0.3)
Ev To Free Cash Flow	(77.87)	(1.65)	(0.93)	(6.79)	(1.96)	(2.06)
Earnings Yield	(0.012)	(0.19)	(1.05)	(0.15)	(0.38)	(0.4)
Net Debt To E B I T D A	15.73	4.09	0.2	0.63	0.97	0.92
Current Ratio	74.62	31.85	12.62	12.33	10.5	9.98
Tangible Book Value Per Share	8.6	7.2	4.94	5.61	6.96	3.73
Shareholders Equity Per Share	8.6	7.2	4.94	5.61	6.96	3.73
Graham Net Net	8.5	13.89	4.66	5.29	6.67	4.38
Enterprise Value Over E B I T D A	(72.1)	(1.24)	(0.75)	(5.44)	(1.44)	(1.51)
Price Earnings Ratio	(83.03)	(5.22)	(0.96)	(6.57)	(2.65)	(2.78)
Price Book Value Ratio	5.59	1.3	0.5	2.5	0.84	0.88
Price Earnings To Growth Ratio	(0.19)	(0.025)	(0.0222)	0.4	(0.94)	(0.9)
Days Of Payables Outstanding	23.9K	5.05	82.33	2.6K	3.0K	2.9K
Price To Operating Cash Flows Ratio	(95.13)	(7.3)	(1.19)	(7.58)	(3.28)	(3.45)
Price To Free Cash Flows Ratio	(94.87)	(7.08)	(1.19)	(7.58)	(3.28)	(3.45)
Ebt Per Ebit	1.03	0.99	0.98	0.92	0.91	1.08
Effective Tax Rate	0.0361	(0.029)	0.002954	0.021	0.0242	0.0158

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:

How To Invest In Olema

Details

Is Olema Stock a good investment?

Details

What is Olema Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.20)

Return On Assets

(0.24)

Return On Equity

(0.39)

The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Olema Historical Financial Ratios

About Olema Financial Ratios Analysis

Olema Pharmaceuticals Financial Ratios Chart

Payables Turnover

Income Quality

Olema Pharmaceuticals fundamentals Correlations

Olema Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Olema Pharmaceuticals fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Operating Cash Flow Per Share
Net Income Per Share	+ 1.0	Free Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio

Capex To Operating Cash Flow	- 0.99	Payables Turnover
Return On Tangible Assets	- 0.98	Roic
Pe Ratio	- 0.97	Roe
Days Of Inventory On Hand	- 0.95	Inventory Turnover
Pe Ratio	- 0.93	Net Income Per Share
Pe Ratio	- 0.93	Free Cash Flow Per Share